Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Drug-induced hypersomnia

Full Text:


 Daytime somnolence may be a symptom of different somatic,  neurological and psychiatric diseases and develop due to abuse  and/or discontinuation of various medications. Drug- induced hypersomnia (DIH) is defined as hypersomnolence  caused by the intake of multiple drugs. DIH is one of the most frequently reported effects and/or side effects of drugs. DIH  prevalence varies widely and can be as high as 75% in patients receiving specific medications. DIH risk factors include elderly  and senile age, impaired drug metabolism, serum drug  concentration, method and frequency of drug administration, single and daily doses of drugs, etc., as in many other drug- induced diseases and syndromes. DIH can occur both due to sedative agents administration and withdrawal of  psychostimulants and other activating psychotropic  medications. Most often, the development of DIH is associated with the use of levodopa-carbidopa, antipsychotics,  antidepressants. The pathogenesis of DIH is complex and multifactorial and is associated with the mechanism of action of  individual drugs and the presence of concomitant diseases. The  article discusses the risk assessment of DIH development due to  various medications, diagnosis and management tactics of  patients with DIH.  

About the Authors

T. M. Ostroumova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

 8, Trubetskaya Str., Build. 2, Moscow 119991, Russia 

O. D. Ostroumova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
Russian Federation

 8, Trubetskaya Str., Build. 2, Moscow 119991, Russia 

 2/1, Barrikadnaya Str., Build. 1, Moscow 125993, Russia 

A. V. Filippova
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
Russian Federation


 2/1, Barrikadnaya Str., Build. 1, Moscow 125993, Russia 

T. F. Guseva
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation

 20, Delegatskaya Str., Build. 1, Moscow 127473, Russia 


1. Sateia MJ. International classification of sleep disorders – third edition: highlights and modifications. Chest. 2014 Nov;146(5):1387-94. doi: 10.1378/chest.14-0970

2. Poluektov MG. Diagnostika i lechenie rasstroystv sna [Diagnosis and treatment of sleep disorders]. Moscow; 2016. P. 193-7 (In Russ.).

3. Gupta R, Seithikurippu R, Almeneessier A, et al. Hypersomnolence and Traffic Safety. Sleep Med Clin. 2017 Sep;12(3):489-99. doi: 10.1016/j.jsmc.2017.03.018. Epub 2017 Jun 8.

4. Pagel JF. Drug-Induced Hypersomnolence. Sleep Med Clin. 2017 Sep;12(3):383-93. doi: 10.1016/j.jsmc.2017.03.011. Epub 2017 Jun 10.

5. Gastel AV. Drug-Induced Insomnia and Excessive Sleepiness. Sleep Med Clin. 2018 Jun;13(2):147-59. doi: 10.1016/j.jsmc.2018.02.001. Epub 2018 Mar 28.

6. Pagel JF, Pandi-Perumal SR, editors. Primary Care Sleep Medicine: A Practical Guide. New York: Springer; 2014. doi: 10.1007/978-1-4939-1185-1

7. Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2018. 1399 р.

8. Dauvilliers Y, Buguet A. Hypersomnia. Dialogues Clin Neurosci. 2005;7(4):347-56. doi: 10.31887/DCNS.2005.7.4/ydauvilliers

9. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000 Apr;59(4):865-89. doi: 10.2165/00003495-200059040-00014

10. Drakatos P, Marples L, Muza R, et al. NREM parasomnias: a treatment approach based upon a retrospective case series of 512 patients. Sleep Med. 2019 Jan;53:181-8. doi: 10.1016/j.sleep.2018.03.021. Epub 2018 Apr 10.

11. Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 2012 Dec 12;12:CD009138. doi: 10.1002/14651858.CD009138.pub2

12. Katona CL, Hunter BN, Bray J. A doubleblind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998 Feb;13(2):100-8. doi: 10.1002/(sici)1099-1166(199802)13:2<100::aid-gps738>;2-j

13. Fagiolini A, Albert U, Ferrando L, et al. A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. Int Clin Psychopharmacol. 2020 May;35(3):137-46. doi: 10.1097/YIC.0000000000000304

14. Rizo C, Deshpande A, Ing A, et al. A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants. J Affect Disord. 2011 Apr;130(1-2):290-3. doi: 10.1016/j.jad.2010.07.027. Epub 2010 Aug 12.

15. Schweitzer PK, Griffin KS. Hypersomnia due to Medication or Substance. In: Reference Module in Neuroscience and Biobehavioral Psychology. Elsevier; 2017. doi: 10.1016/b978-

16. 0-12-809324-5.01065-8

17. Crocco EA, Cruz-Ortiz С, Camfield K. Pharmacological Management of Anxiety Disorders in the Elderly. Curr Treat Options Psych. 2017 Mar;4(1):33-46. doi: 10.1007/s40501-017-0102-4. Epub 2017 Feb 10.

18. Miller DD, Pharm D. Atypical Antipsychotics: Sleep, Sedation, and Efficacy. Prim Care Companion. J Clin Psychiatry. 2004;6(Suppl 2):3-7.

19. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19.

20. Elger CE, Stefan H, Mann A, at al. A 24-week multicenter, randomized, doubleblind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res. 2010 Feb;88(2-3):255-63. doi: 10.1016/j.eplepsyres.2009.12.003. Epub 2010 Jan 12.

21. Bonanni E, Galli R, Maestri M, et al. Daytime Sleepiness in Epilepsy Patients Receiving Topiramate Monotherapy. Epilepsia. 2004 Apr;45(4):333-7. doi: 10.1111/j.0013-9580.2004.47803.x

22. Reife R, Pledger G, Wu S. Topiramate as Add-On Therapy: Pooled Analysis of Randomized Controlled Trials in Adults. Epilepsia. 2000;41(S1):66-71. doi: 10.1111/j.1528-1157.2000.tb02175.x

23. Biton V, Krauss G, Vasquez-Santana B, et al. A randomized, doubleblind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia. 2011 Feb;52(2):234-42. doi: 10.1111/j.1528-1167.2010.02729.x. Epub 2010 Sep 30.

24. Nodel MP. Hypersomnia and circadian disturbances in Parkinson’s disease. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(4):45-50. doi: 10.14412/2074-2711-2016-4-45-50 (In Russ.).

25. Levin OS, Lyashenko EA. Sleep disturbances in Parkinson's disease. Farmateka = Pharmateca. 2014;10(3):12-9 (In Russ.).

26. Schweitzer PK, Randazzo AC. Drugs that disturb sleep and wakefulness. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th ed. Philadelphia: Elsevier; 2017. P. 480-98.

27. Rosen G, Harris AK, Liu M, et al. The effects of Dexamethasone on sleep in young children with Acute Lymphoblastic Leukemia. Sleep Med. 2015 Apr;16(4):503-9. doi: 10.1016/j.sleep.2014.11.002. Epub 2015 Feb 2.

28. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5. doi: 10.1093/sleep/14.6.540

29. Gros P, Videnovic A. Overview of Sleep and Circadian Rhythm Disorders in Parkinson Disease. Clin Geriatr Med. 2020 Feb;36(1):119-30. doi: 10.1016/j.cger.2019.09.005. Epub 2019 Sep 6.

30. Sychev DA, Ostroumova OD, Pereverzev AP, et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Farmakonadzor. Farmateka = Pharmacovigilance. Pharmateca. 2020;(6):113-26. doi: 10.18565/pharmateca.2020.6.113-126 (In Russ.).

31. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Greenblatt Clin Pharmacol. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154


For citations:

Ostroumova T.M., Ostroumova O.D., Filippova A.V., Guseva T.F. Drug-induced hypersomnia. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(2):117-122.

Views: 504

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)